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Abstract
this  manuscript  is  communicated  by  the  german
AIds  society  (dAIg)  (www.daignet.de).  It  summa-
rizes a series of presentations and discussions during a
workshop on immune activation due to HIV infection.
the workshop was held on november 22nd 2008 in
Hamburg,  germany.  It  was  organized  by  the  IcH
Hamburg  under  the  auspices  of  the  german  AIds
society (dAIg e.V.).  
bAckgRound
HIV infection is characterized by progressive cd4+ t-
cell depletion and chronic immune activaton, resulting
in polyclonal hypergammaglobulinaemia as well as in-
creased turnover and apoptosis rates of t-cells [1-11].
Immune activation per se is a physiological response.
the question has to be raised, however, if the persis-
tence of HIV-induced immune activation over many
years actually overstretches regenerative and homeo-
static mechanisms, which are driven by increased cell
turnover, and thereby leads to immune exhaustion.
Highly  active  antiretroviral  therapy  (HAARt)  re-
duces immune activation via a reduction of viral repli-
cation. It is as yet unclear, however, if it can be contin-
ued  safely  and  effectively  for  decades  in  order  to
achieve a normal life expectancy. furthermore, some
patients  retain  elevated  levels  of  immune  activation
despite successful HAARt. A detailed analysis of the
mechanisms and its consequences could therefore re-
veal  important  novel  complementary  approaches  to
HIV therapy, which could help to overcome the limita-
tions of current therapies.
„IMMunE ActIVAtIon And IMMunE functIon“ 
(c. scheller, W￼rzburg)
the immune system is based on innate and adaptive
immune responses. Innate responses are older in evo-
lution  and  are  characterized  both  by  immune  cells
such as macrophages and natural killer cells recogniz-
ing conserved structures of microorganisms, and the
release of cytokines. Adaptive immunity comprises b-
cell-  and  t-cell-mediated  responses.  Approximately
1012 different binding specificities of cell surface re-
ceptors induce activation and differentiation to effec-
tor cells following antigen contact. A fraction of effec-
tor  cells  returns  to  a  deactivated,  resting  „memory“
state within a couple of days, from which they can be
awakened very quickly upon reexposure to the same
antigen (“acquired immunity”). the other activated ef-
fector cells then proceed to fulfil their function and
undergo apoptosis after 2-3 weeks. Apoptosis is the
natural  consequence  of  activation.  the  absence  of
programmed cell death would lead to the accumula-
tion of senescent, non-functional effector cells in the
sense of a „super-leukemia”. 
- Chronic immune activation
Most infectious agents are cleared by the immune sys-
tem after days to weeks. some are not eradicated but
controlled  to  the  extent  of  a  latent,  clinically  stable
phase, and immune activation is reduced subsequently.
In HIV infection, however, it persists. Recent studies
suggest several reasons. cd4+ t-cells are massively de-
pleted fromthe gastrointestinal lymphatic tissue(gAlt)
during acute HIV infection, but also in later stages of
the infection [12, 13]. this affects mainly the effector
site (lamina propria), less so the inductive site (Peyer’s
plaques) [14]. It is estimated that half of the cd4+ t-
cells of the body reside in the gAlt. they display the
“memory” phenotype and express ccR5, the dominant
coreceptor of HIV in the early phase of infection. 
the conditions for the first peak of virus replica-
tion are ideal within the gastrointestinal tract. As early
as several days following infection, most of the cells
are infected and succumb to the early burst of replica-
tion, most likely due to the viral cytopathic effect. this
probably leads to an irreversible loss of a large pro-
portion of the memory cd4+ t-cell pool. studies in
subjects on antiretroviral therapy show that the num-
ber of cd4+ t-cells in the gAlt does not return to
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this feature of HIV infection, however, is also ob-
served in non-pathogenic animal models, i.e. monkeys
infected by sIV variants that do not cause disease in
their  natural  host  [16,  17]  such  as  sooty  mangabeys
and African green monkeys.
severe  gastrointestinal  cd4+ t-cell  depletion  is
subsequently associated with the translocation of mi-
crobial antigens from the gut lumen into the host tis-
sue, leading to activation of innate and adaptive im-
mune responses. depending on the stage of HIV in-
fection,  levels  of  lipopolysaccharides  (lPs)  in  the
serum are increased, which stem from gram-negative
bacteria in the gut [4]. sooty mangabeys and African
green monkeys, however, exhibit no increase of lPs
translocation  and  immune  activation.  during  anti-
retroviral therapy lPs levels are reduced, but do not
reach the levels of normal controls. 
Moreover, as a consequence of the development of
HIV-specific t-cell responses, stimulation and expan-
sion of cd4+ t-cells continuously provides new tar-
get-cells  for  HIV  replication.  the  continuation  of
this state over many years apparently overstretches the
regenerative  capacities  of  the  immune  system,  and
AIds develops.
- Immune senescence
like all cells of the body, the immune system underlies
ageing.  In  the  process  of  t-cell  receptor  rearrange-
ment during t-cell maturation in the thymus, excised
t-cell receptor dnA persists in the cells (t-cell-recep-
tor excision circles, or tREcs). As tREcs are not du-
plicated during mitosis, the content of tREcs in the
blood is diluted with ongoing cell proliferation. thus,
tREc content reflects both thymic output and pre-
ceding rounds of t-cell proliferation with an accumu-
lation of “older” t-cells. HIV infection leads to a shift
in  the  average  “immunological  age”  of  peripheral
blood t-cells: tREc content is markedly recuced in t-
cells during HIV infection, as compared with an unin-
fected person. telomer shortening during cell division
serves as another marker of cell senescence. both im-
paired thymic t-cell generation as well as chronic im-
mune activation resulting in increased numbers of ter-
minally  differentiated  t-cells  probably  contribute  to
this  phenomenon  and  result  in  severe  t-cell  lym-
phopenia in the course of progressive AIds.
In addition to immune senescence, HIV infection
leads to release of inflammatory and pro-inflammato-
ry  cytokines  that  initiate  mechanisms  known  from
physiological ageing, such as osteoporosis, arterioscle-
rosis, and HIV dementia („inflamaging“).
tHE RolE of VIRAl PRotEIns, oR: WHAt cAn WE
lEARn fRoM MonkEys ? 
(J. M￼nch, ulm)
the  AIds  epidemic  is  clearly  recognized  as  a  viral
zoonosis [18]. More than 30 primate species in Africa
have been shown to be infected with simian immuno  -
deficiency viruses (sIV). the causative agent of AIds,
HIV-1, arose by transmission of simian immunodefi-
ciency virus (sIV) from a subspecies of chimpanzees
(sIVcpz) into the human population in the first half
of the last century [19-21]. HIV-2, that is less patho-
genic in humans than HIV-1, has its closest ancestors
in sIVs found in sooty mangabeys (sIVsm) [22]. Inter-
estingly, almost all sIVs do not cause immunodeficien-
cy or AIds like symptoms in their natural African pri-
mate host despite high viral loads in some species. the
only exception to date is sIVcpz that has recently been
demonstrated to be associated with an increased mor-
tality and AIds-like immunopathology in wild sIVcpz
infected chimpanzees [23]. thus, HIV-1 and its ances-
tors  from  chimpanzees  cause  immune  dysfunction
whereas HIV-2 and remaining sIVs are less or non-
pathogenic in their respective hosts [24]. Elucidating
the differences in pathogenic versus non-pathogenic
infection in humans and monkeys is thus a key to un-
derstand AIds pathogenesis, it has become clear that
one major difference to non-pathogenic sIV infection
is the chronic generalized activation of the immune
system  in  progressive  AIds  in  humans.  Hyper-im-
mune activation causes increased t-cell turnover and
might ultimately result in the loss of cd4+ t-cells, the
hallmark of AIds. High plasma viremia, a viral cyto  -
pathic effect for cd4+ t-cells, and the early depletion
of cd4+ t-cells from the gastrointestinal tract occur
similarly in both the pathogenic and the apathogenic
condition.
- HIV-1 Nef  – a master manipulator of  the immune 
response
All sIVs and HIVs encode for the multifunctional nef
protein.  nef  is  expressed  early  in  the  viral  life 
cycle and helps the virus to evade the immune system
by  interfering  with  the  cellular  activation  state  and
modulating the expression levels of several cell surface
factors [25]. for example, nef from all immunodefi-
ciency viruses down-regulates MHc class I molecules
from the surface of the infected cell, thereby prevent-
ing lysis by cytotoxic cd8 t-cells [26, 27].  Interest-
ingly, expression of HIV-1 nef alone in t-cells results
in  a  hyper-responsiveness  to  activation  [28].  this
“priming” for activation of infected cells could create
an ideal environment for HIV replication and could
thus  contribute  to  the  increased  immune  activation
and t-cell apotosis in chronic HIV-1 infection. Analy-
sis of nefs derived from pathogenic HIV-1/sIVcpz
and non-pathogenic HIV-2/sIVs showed differences
in  their  ability  to  induce  a  cellular  hyper-responsive
state [29]. nef alleles from the great majority of pri-
mate lentiviruses, including HIV-2, are able to down-
modulate  the  t-cell  receptor  (tcR)-cd3  complex
from infected t-cells [29]. since cd3 is crucial for t-
cell  activation,  HIV-2/sIV  nef  expressing  cells  did
not  respond  to  t-cell  activation  whereas  nef  alleles
from HIV-1 and sIVcpz fail to down-regulate tcR-
cd3. HIV-1 infected cells hyper-respond to activation
and  die  due  to  activation-induced  cell  death.  thus,
nef-mediated  suppression  of  t-cell  activation  by
down-regulating  cd3  is  a  fundamental  property  of
non-pathogenic primate lentiviruses that likely evolved
to maintain viral persistence in the context of an intact
host  immune  system  [29].  Pathogenic  sIVcpz  and
HIV-1 lost the ability to down-modulate cd3, thereby
resulting in higher rates of t-cell activation and cell
death - the hallmarks of AIds [29].
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served differences in disease progression in humans or
naturally  infected  primates.  other  viral  proteins  like
Env or tat have also been discussed to be implicated
in driving a chronic immune activation, but are investi-
gated less thoroughly. Host factors play a central role
and determine disease outcome as well. for example:
infection of Asian rhesus macaques with sIVsm that
is able to down-regulate cd3 results in an AIds-like
disease, whereas the same virus is non-pathogenic in
sooty  mangabeys  and  moderately  pathogenic  in  hu-
mans  (HIV-2)  [30].  In  summary,  immune  activation
plays  an  important  role  in  AIds  pathogenesis.  the
underlying  mechanisms  are  multifactorial  in  nature
and involve complex interactions between host and vi-
ral factors. future studies aimed to understand chronic
immune activation in detail are central for a better un-
derstanding of AIds disease progression that could
lead to new treatment options. 
IMMunE ActIVAtIon by HIV: IMPAct on nAtuRAl
HIstoRy
(J. Rockstroh, bonn)
the natural course of HIV infection is characterized
by primary infection, consecutive progressive cd4+ t-
cell loss, an increasing plasma viremia, and by the on-
set of clinical complications. there is strong evidence
that HIV-1 itself has a direct impact on immune acti-
vation: it reaches its highest level during acute infec-
tion. When antiretroviral therapy is started, immune
activation markers decrease within days and reincrease
when plasma viremia increases following treatment in-
terruption. 
- Association with morbidity and mortality
before the era of modern antiretroviral therapy, HIV-
infected hemophiliacs were shown to have increased
b2-microglobuline  and  IgA  levels,  which  correlate
with survival [31].
Activation of cd4+ and cd8+ t-cells, as assessed
by  the  expression  of  cd38,  is  associated  with  de-
creased survival in advanced infection (<50 cd4+ t-
cells/ﾵl),  independent  from  plasma  viremia  and  viral
coreceptor tropism [32]. Increased cd8+ t-cell activa-
tion, as assessed by cd38 expression, and increased ex-
pression of the apoptosis marker Pd-1 have been iden-
tified as prognostic markers for disease progression, in-
dependent from cd4+ t-cell count, but probably cou-
pled to virus replication [33-39]. serum RAntEs as
another marker of immune activation correlates with
cd8+ t-cell activation [40]. Recently, a loss of regula-
tory cd4+ t-cells has been suggested as a possible fac-
tor in the maintenance of immune activation [41]. 
low-level plasma viremia in treated patients (3- 400
copies/ml) activates the immune system to a similar
extent as detectable plasma viremia (>400 copies/ml).
Apparently, treatment does not completely normalize
immune activation, especially if low-level replication
continues [42].
the results of a large trial investigating continued
versus intermittent therapy (sMARt study) have rein-
forced  the  discussion  about  immune  activation:  pa-
tients in the treatment interruption arm, apart from
being  at  higher  risk  for  HIV-related  complications,
also had higher rates of non AIds-associated compli-
cations  such  as  cardiovascular,  renal,  and  hepatic
events  than  subjects  in  the  continuous  therapy  arm
[43]. the increased risk of death during treatment in-
terruption was paralleled by increased d-dimer, Il-6,
and  hs-cRP  levels,  indicating  a  link  between  virus
replication, inflammation, and risk of progression.
- Different hypotheses to explain CD4+ T-cell depletion
Plasma  viremia  in  HIV-infected  and  in  HIV/HcV-
coinfected patients is positively associated with apop-
tosis rate; when antiretroviral therapy is started, apop-
tosis is reduced [44]. the upregulation of different im-
munological effector mechanisms prevents a simplistic
conclusion regarding the importance of a single mech-
anism for cd4+ t-cell depletion. 
Explorative gene expression analyses performed on
intestinal tract biopsies show an upregulation of inter-
feron, chemotaxis, cell cycling, and apoptosis in acute-
ly HIV-infected subjects, and a downregulation of fac-
tors affecting lipid and glycogen metabolism [45]. 
A variety of mechanisms for immune hyperactiva-
tion with subsequent apoptosis are discussed in addi-
tion to those mentioned before: bystander activation,
homoeostatic  proliferation,  t-cell  responses  against
autoantigens or against intestinal microorganisms, and
a progressive loss of regulatory t-cells. As a current
hypothesis based on primate animal models it is sug-
gested that activation of the toll-like receptor tlR-7
leads to the release of proinflammatory cytokines and
subsequently to the activation of t-cells [46].
IMMunE ActIVAtIon In lyMPHoId tIssuE
(k. tenner-Racz, Hamburg)
Physiological immune responses require a strict coor-
dination  of  spatially  separated  immunological  com-
partments. In the secondary lymphatic tissue (lymph
nodes, spleen, and mucosa-associated lymphoid tissue
[MAlt]), antigen-dependent activation and differenti-
ation of na￯ve t and b-cells into effector and memory
populations takes place. this requires an interaction
between b-cells, different groups of t-cells, and anti-
gen-presenting cells as well as migration of lympho-
cytes into the t-cell- and b-cell dependent zone. such
migration is essential for a normal immune function.
Within 12 days, lymph nodes turn over the equivalence
of their own weight in circulating lymphocytes [47].
this high turnover is facilitated by a high blood flow
(minimum of 1 ml/min/g of lymph node tissue) and
a high circulation of lymph node fluid (10 ml/hr/g
lymph node tissue). In case of an antigenic stimulus,
this flow can be up-regulated by two- to threefold. 
Here we summarize some aspects of the activation
of the b-cell dependent zone. It is important to keep in
mind that germinal centres (gc) play a central role in
HIV disease pathogenesis as an important reservoir for
HIV  (summarized  in  [48]).  Importantly,  gc  support
the  differentiation  of  memory  b-cells  and  long-lived
antibody-secreting cells during infection or upon vacci-
nation. this function requires the help of t-cells. Ac-
cording to their effector function and cytokine produc-
tion profile, the t-cells are classified as th1 (Ifn-g, Il-
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larized t-cells (no Il-4 and Ifn-g production, but effi-
cient induction of immunoglobuline production).
the secondary follicles consisting of a mantle zone
and a gc are composed of b-cells, follicular dendritic
cells  and  tingible  body  macrophages,  and  cd4+ t-
cells. A few bone marrow-derived dendritic cells are
also present [49].
the cd4+ cells that contribute approximately 10%
to the cell pool within the gc, is distinct from the
cd4+ cells  in  peripheral  blood  or  the  t-cell-depen-
dent zone of the lymphoid tissue. they represent fol-
licular t helper (tfH) cells. these cells are only present
in the secondary lymphoid tissue and do not circulate
in the peripheral blood [50]. they are non-polarized,
thus, they produce neither Ifn-g nor Il-4. neverthe-
less, tfH cells are very efficient in stimulating Ig pro-
duction [50-53]. nearly 60-75% of the cells express
cd57. 
tfH already had contact with an antigen and ex-
press cd69, but not cd25. A characteristic feature of
these cells is the upregulation of cXcR5 which is the
receptor for cXc-chemokine ligand 13 (cXcl13). In
mice lacking cXcl13 or its receptor cXcR5, the ar-
chitecture of the follicles and the differentiation of t
and  b-cells  are  disturbed.  cXcR5-dependent  t-cell
positioning  is  important  not  only  in  the  formation
and expansion of gc, but also for the induction of
immunoglobulin isotype class switching and for the
development  of  long-lived  antibody-secreting  cells
[54]. 
cXcl13 is a „b-cell attracting chemokine 1“and fa-
cilitates the follicular homing of b and t-cells. freshly
isolated cd4+cd57+ tfH cells show a high expression
of cXcl13 mRnA. Without persistent t-cell activa-
tion in culture, however, they are unable to produce
cXcl13 [55]. this chemokine is an important con-
tributor to the localization of tfH cells to the primary
follicles as well as to gc formation [51, 52, 54, 56].
the chemokine cXcl13 promotes follicular homing
by b and t-cells during chronic inflammation. It is a
component of the de novo formation of lymphatic tis-
sue  [57-60].  Although  HIV-1  infection  is  associated
with b-cell abnormalities and severely altered lymph
node  histology,  including  the  b-dependent  zone,  no
attention has been paid to the tissue distribution of
this chemokine.  
We investigated lymph nodes from HIV-1-infected
patients  and  HIV-negative  individuals.  Previous  re-
ports  have  indicated  follicular  dendritic  cells  (fdc)
and follicular stromal cells as a source of cXcl13 [56,
59, 61]. In agreement with these finding, we also de-
tected  cXcl13  protein  in  a  pattern  resembling  the
fdc  network.  However,  only  a  few  gcs  contained
this chemokine in both HIV-1 samples and controls.
As we reported recently [62], we found that the main
expression  of  cXcl13  was  localized  in  immature
cd1a+dcs of the t-dependent zone. the expression
was less prominent in cd83+ mature dcs. this could
suggest that the cXcl13 protein might be lost during
dc  maturation.  the  numbers  of  dc  expressing
cXcl13  in  lymph  nodes  from  HIV-negative  cases
were higher than in HIV-positive subjects. the overall
lower content in cXcl13 in HIV-positive patients was
not influenced by six months of HAARt. the rela-
tionship  between  cXcl13  producing  dc  and  the
pathogenesis of HIV disease, however, remains uncer-
tain. Additional in situ and in vitro investigations are
required in order to further characterize functions of
these cells.
cHEMokInEs, cytokInEs, HIV – WHAt A MEss? 
(g. behrens, Hannover)
chemokines play a central role for the migration and
activation  of  immune  cells.  At  least  20  different
chemokine receptors and approximately 50 different
chemokines have been described as their ligands [63].
these inflammatory chemokines differ from homeo-
static chemokines in that the latter are active during
normal physiological conditions.
- Complex interplay
the complex interplay of chemokines is characterized
by redundance, i.e. by many ligands binding to differ-
ent receptors, and these interactions are directed by
compartmentalisation,  combinatory  interactions  and
alterations  in  activity  by  matrix  metalloproteases.
chemokines  are  present  as  monomers,  dimers,
tetramers, and other oligomers. different chemokine
receptors of the two major forms ccR and cXcR are
associated with different diseases. 
chemokine  receptors  are  expressed  by  dendritic
cells (dc) and t-cells [64]. Immature dcs exhibit a
wide range of chemokine receptors that are also im-
portant for their migration. 
the contact with a pathogen provides the impulse
for immature dcs to become active („licensed dc“).
In the process of maturation and activation ccR7 is
expressed, which lets the cell migrate along a ccl16
and ccl21 gradient into the lymph node, where the
dc matures completely. subsequently, co-stimulatory
molecules are upregulated, as well as MHc class I and
II, and t-cells are activated. 
It is hypothesized that immature dcs promote t-
cell tolerance, whereas regulatory t-cells and mature
dcs lead to protective t-cell responses. 
chemokine receptors are also used by pathogens.
toxoplasma gondii evades immune responses by bind-
ing to ccR5. due to the lower efficacy of a th1 re-
sponse against t. gondii, this results in a balance, and
the parasite can persist in the host. HIV also activates
dcs, with subsequent t-cell activation and prolifera-
tion, which in turn provides HIV with potential target
cells for replication. chemokines also regulate effector
cells  and  regulatory  t-cells  which  display  different
chemokine receptors.
- CCL3L1 blocks CCR5
the chemokin-ligand 3–like 1 (ccl3l1) is a ligand
of the ccR5 receptor. the gene for ccl3l1 occurs
in several copies, and the number of duplications is
different between populations and individuals. 
In  a  recent  cohort  study,  persons  with  a  specific
combination  of  ccR5  and  ccl3l1  displayed  a  re-
duced  immune  response  and  a  lower  cd4+ t-cell
number [65]. As a consequence, a lower expression of
receptors, although in principle protective with respect
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cells. In turn, an altered expression of the ligand could
stimulate the decay of the receptor and thereby limit
HIV replication, as well as increasing the migration of
effector cells. In this cohort analysis the ccl3l1 con-
centration  had  a  greater  impact  on  HIV  prognosis
than the presence of a functional ccR5 receptor. 
IMPAct of IMMunE ActIVAtIon on tHE PRognosIs
of HAARt 
(M. stoll, Hannover)
It is frequently assumed that the increase of cd4+ t-
cell counts during HAARt-mediated suppression of
virus replication totally mirrors the reversion of HIV-
induced immunodeficiency. However, this view does
not take the consequences of immune activation into
account.  the  results  of  the  sMARt  study  showed
that deaths due to opportunistic events and other, not
classically HIV-associated events occurred more fre-
quently in subjects randomized to the treatment inter-
ruption arm as early as 16 months into the study, as
compared with subjects with continued therapy [43].
treatment interruption was associated with a higher
risk of opportunistic disease and death independent
from  cd4+ t-cell  count.  A  sub-analysis  of  the
sMARt study showed that the increase of several in-
flammatory serum markers with an established prog-
nostic role for cardiovascular events (hs-cRP, inter-
leukin-6,  amyloid  A  and  P,  d-dimers  and  the  pro-
thrombin  fragments  1  and  2  (f1.2))  was  associated
with increased mortality and, of note, also with car-
diovascular events [66]. 
Meanwhile, immune activation is considered in the
model to explain the effects of HAARt. It is postulat-
ed that, in addition to reducing virus replication and
thereby increasing cd4+ t-cell counts, HAARt also
reduces  immune  activation  and  the  risks  associated
with chronic inflammation. 
of note, a variety of organ systems appear to be af-
fected by chronic inflammation. As a consequence, the
reduction  of  immune  activation  by  HAARt  could
prevent non-opportunistic events such as arterioscle-
rosis, myocardial infarction, liver diseases, and impair-
ment  of  renal  function.  for  these  events,  however,
other risk factors have to be taken into account, such
as age, HAARt toxicity, smoking, illicit drugs, alcohol,
nutrition, level of physical activity, and genetic disposi-
tion.
there is no doubt as to whether HAARt reduces
immune  activation.  this  was  demonstrated  several
years ago [67]. It is not clear, however, if immune acti-
vation is completely normalized by HAARt. 
- Do we have to start HAART earlier ?
the pendulum of treatment indication currently ap-
pears to swing back towards an earlier start of therapy,
resulting in the recommendation to start HAARt at a
cd4+ t-cell count of less than 350/ﾵl in most guide-
lines.
the leading argument for starting treatment earlier
is  the  prevention  of  opportunistic  infections  and
death, but the prevention of non-opportunistic events
is increasingly being recognized as another argument
for  an  early  start.  starting  HAARt  at  even  higher
cd4+ t-cell counts (>500/ﾵl) is currently supported
only by a recent cohort analysis [68], which has some
methodological  issues.  A  prospective  clinical  trial
(stARt study) is under preparation and will likely re-
solve the issue.
the impact of treatment-emergent long-term toxic-
ities on the rate of events and the balance between
those and the beneficial effect of HAARt on these
event cannot be fully judged at present. the risk of
treatment  interruption  requires  preparedness  of  the
patients for life-long HAARt, especially when treat-
ment is started early.
- Late HAART: how urgent is it ?
In patients with late initiation of HAARt („late pre-
senters“), it should not be delayed, with the possible
exception of subjects with concomitant mycobacte-
riosis. the untoward effect of a possible immune re-
constitutional inflammatory syndrome (IRIs) and ad-
verse  drug  interactions  does  not  outweigh  the  im-
provement  of  prognosis  if  treatment  is  started  2
weeks after diagnosis. this recommendation is based
on the prospective Actg A5164 study, which did not
include  patients  with  mycobacteriosis  [69],  and  the
evaluation of a south-African cohort, in which IRIs
occurred in all patients who initiated HAARt within
30  days  after  diagnosis  of  tuberculosis.  A  detailed
analysis of the 160 subjects in this cohort revealed
that 19 of them developed IRIs, two of them fatal.
However, ten deaths occurred prior to the initiation
of HAARt [70]. 
A larger brazilian cohort study based on 963 incident
tuberculosis cases among more than 15000 HIV-infect-
ed subjects showed only a small difference in survival
when HAARt was initiated within 60, 61-180, or >180
days after the start of tuberculostatic therapy [71]. 
- Arguments against immediate HAART for late 
presenters
the data that argues for an immediate initiation of
HAARt is based on studies from countries in which
HIV  care  is  restricted  by  economic  constraints. 
de-masked  opportunistic  infections  which  manifest
as  IRIs  show  the  detrimental  potential  of  un-
treated opportunistic infections after HAARt initia-
tion.
further  studies  should  provide  a  basis  for  active
risk management, by which patients at high risk for
IRIs can be identified beforehand.
Preliminary  data  suggests  an  increased  risk  with
certain tnf polymorphisms, cytokine receptor poly-
morphisms,  an  association  with  HlA  antigens  and
with certain patterns of immune activation (i.e. distur-
bances  in  the  relationship  between  th1  and  th2
cells).
the optimal clinical approach to this basically phys-
iological response of the immune system is not well-
defined and requires further investigation.
It is conceivable that in the future immunomodula-
tory or transient immunosuppressive approaches will
be utilized in order to prevent or mitigate IRIs. they
could be limited to subjects at high risk identified by
novel parameters yet to be defined.
EuRoPEAn JouRnAl of MEdIcAl REsEARcH January 29, 2010 5
1. Stellbrink Rev_Umbruchvorlage  20.01.10  14:57  Seite 5AbAcAVIR And MyocARdIAl InfARctIon: Is It
IMMunE ActIVAtIon ? 
(th. Harrer, Erlangen)
the relationship between HAARt and cardivascular
risk cannot be explained solely and mechanistically by
the mode of action of therapy. despite an equivocal
effect of a HAARt regimen that includes abacavir on
the reduction of immune activation, the prospective
d:A:d  study  on  33.347  HIV-infected  patients  from
eleven cohorts found an association between the cur-
rent or recent use of abacavir and myocardial infarc-
tion or equivalent cardiovascular events. this also ap-
plies to didanosine, although to a lesser extent [72]. A
total  of  517  subjects  (1,6%)  suffered  an  episode  of
myocardial infarction. Recent or current abacavir use
was  associated  with  a  90%  risk  increase.  Recent  di-
danosine use showed a 47% risk elevation. there was
no association with stroke. 
the risk increase was highest for subjects with a pre  -
  existing cardiovascular risk elevation. there was no in-
crease of risk for past use of abacavir or didanosine1.
the possibility of selection bias (i.e. a preference
for abacavir by physicians due to its favourable lipid
profile) cannot be fully excluded, although it appears
improbable in the context of similar results from oth-
er studies. An analysis of the sMARt study revealed
an  increased  risk  of  cardiovascular  events  of  any
severity for patients on abacavir without didanosine at
baseline (22.4%; n = 259). the risk for myocardial in-
farction was also elevated (n = 19). there was no asso-
ciation with didanosine use in this analysis [73]. 
A retrospective analysis of 54 prospective clinical
studies performed by glaxosmithkline, which includ-
ed 14.683 therapie-na￯ve and pretreated patients, did
not show this association [74]. A major difference be-
tween these studies and cohorts is the underrepresen-
tation of patients at high risk of cardiovascular events. 
- Abacavir and inflammatory markers
the mechanism of increased risk is still unclear. the
sMARt study showed an elevation of hs-cRP and in-
terleukin-6 in patients on abacavir, independent from
continuous therapy or treatment interruption. cardio-
vascular risk in the continuous therapy arm depended
on the presence of at least five coronary risk markers.
A  retrospective  analysis  of  the  HEAt  study,  in
which abacavir+3tc was compared with tenofovir +
ftc, both combined with lopinavir/r, did not show a
difference in the plasma levels of inflammatory para-
meters. these markers declined until week 96 in both
arms [75]. 
the increased risk associated with abacavir use ap-
pears not to be a general immune-activating effect or a
lesser reduction of HIV-associated immune activation. 
MRI studies of the long-term effects on coronary
artery sclerosis performed on 48 patients in Erlangen
revealed coronary artery calcifications in 28 patients
without  abacavir,  21  on  abacavir,  and  in  12  control
subjects  (Ropers  et  al.,  unpublished  observation).
there were no differences in the extent of calcifica-
tion of coronary arteries, aortic valve, and mitral valve.
cd4+ and cd8+ cells and viral load as well as plasma
levels of tnf-alpha, Il-6, and of hs-cRP were also
comparable. this would be compatible with a short-
term effect. 
- Do abacavir-associated cardiovascular events represent a 
hypersensitivity reaction ?
the question has to be raised if the increased cardio-
vascular risk represents a reaction similar to the well-
known  inflammatory  reaction  associated  with  the
presence of the HlA-b*5701 antigen. 
It is hypothesized that abacavir is metabolized with-
in  antigen-presenting  cells,  and  that  a  metabolite  is
presented in the context of HlA-b’5701 as an antigen
[76]. 
the  resulting  secretion  of  cytokines  would  then
lead to an inflammatory syndrome, which could prop-
agate myocardial infarction in the presence of preex-
isting risk factors.
In  the  cohort  analyses  mentioned  above,  HlA-
b*5701  testing  was  not  performed  routinely.  there-
fore, it appears conceivable that an “abortive” hyper-
sensitivity reaction actually precipitated myocardial in-
farction.
An analysis of the Erlangen cohort so far was un-
able  to  confirm  this  hypothesis:  28  (7.8%)  of  358
HlA-typed patients were HlA-b*5701-positive. sev-
en of nine subjects in the cohort who had received a
stent or had experienced myocardial infarction had re-
ceived abacavir. However, only one subject was HlA-
b*5701-positive.  so  far  the  relationship  between  in-
flammatory  reactions  and  abacavir  use  in  HlA-
b*5701-negative individuals remains speculative. It has
to be assessed in prospective clinical studies such as
AssERt, which are currently ongoing.
HIV And cARdIoVAsculAR RIsk
(s. baldus, Hamburg)
HIV-infected subjects show a 75% higher incidence of
cardiovascular  events  than  an  HIV-negative  control
group, which increases even further with age [77]. In
HIV infection, coronary heart disease is characterized
by an increased proliferation of fibroblasts, increased
thrombocyte activation, decreased vascular relaxation,
direct viral effects and effects of antiretroviral therapy. 
- HIV accelerates coronary atherosclerosis
It is currently believed that acute coronary occlusion
in the setting of coronary atherosclerosis is a highly
dynamic process with plaque rupture and subsequent
thrombus formation, rather than a slowly progressive
occlusion  of  the  vessel.  A  vulnerable  plaque  with  a
high risk of rupture due to a thin covering layer can-
not be identified or predicted by angiography, in con-
trast to plaques with a thick layer, which are less likely
to rupture [77, 78]. 
HIV has a high affinity to endothelium and locally
induces the production of the cytokines interleukin-
1￟ and interleukin-6, which activate lymphocytes and
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cell membrane permeability. the virus attracts mono-
cytes, which invade into the vascular endothelium to-
gether  with  ldl  particles.  Residing  macrophages
(„foamy  cells“)  subsequently  oxidize  the  ldl  and
take up lipids together with monocytes. these cells
also release cytokines, which stimulate the prolifera-
tion of smooth muscle cells and accelerate the growth
of the plaque. If fibroblast or leukocyte metallopro-
teinases react in the vicinity of the thin covering layer,
it can rupture and lead to the adhesion of thrombo-
cytes.
- Vascular function as a prognostic parameter 
Vascular  function  represents  an  essential  parameter
for the prediction of cardiovascular risk. leukocyte
and thrombocyte adhesion, proliferation of smooth
muscle cells and fibroblasts, and the expression of ad-
hesion molecules on the endothelial surface are regu-
lated by signal molecules which are produced in the
endothelium. the most important and best character-
ized  anti-inflammatory  signal  molecule  is  nitric
monoxide (no). It is produced in the endothelium by
an no synthase and is responsible for the downregu-
lation of the processes mentioned above. due to its
long half-life, the radical can permeate into smooth
muscle tissue, where it activates additional signalling
cascades which lead to the relaxation of smooth mus-
cle cells.
Meanwhile, the measurement of no bioavailability
by ultrasound or invasive methods is established for
determining cardiovascular risk, especially in patients
with cardiovascular diseases.
no as a surrogate parameter for cardiovascular risk
might  be  better  than  inflammatory  markers.  Its
bioavailability is probably regulated by increased oxi-
dation or inactivation of no by superoxide and per-
oxidases, especially myeloperoxidase, from monocytes,
macrophages, and neutrophils. the relevance of no
depletion by superoxide and myeloperoxidase is illus-
trated by animal experiments, in which the humoral
and structural integrity of the endothelium was altered
by these two factors.
Endothelial  vasoreactivity  provides  an  important
prognostic  information.  the  blood  flow-dependent
dilatation of the brachial artery is easy to determine:
occlusion of the vessel for five minutes leads to is-
chemia. the increased vascular blood flow following
ischemia is no-mediated. HIV-infected subjects show
a dilatation of the brachial artery of only 3.5%, as op-
posed to 10% in healthy controls [79]. 
- Cardiovascular risk factors in HIV infection
In addition to direct effects of HIV on the endotheli-
um, changes in the cardiovascular risk profile impact
on the risk of cardiovascular events: the prevalence
of  hypertension,  diabetes  and  dyslipidemia  is  in-
creased in HIV infection [77, 78]. It has to be stated
clearly  that  especially  a  diabetic  patient  has  to  be
viewed like a patient with proven coronary heart dis-
ease, as their risks are equivalent. 
- HAART accelerates coronary atherosclerosis
the d:A:d cohort showed a 16% increase of cardio-
vascular risk per year of protease inhibitor therapy, re-
sulting in a doubling of risk over five years [80]. A
small cross-sectional study in 83 HIV-positive children
showed  an  impaired  endothelial  function  in  the  PI-
trea  ted group compared with children not receiving a
PI [81]. A study on carotid intima media thickness in
141 HIV-infected patients showed an increase with PI
treat  ment [82]. several factors contribute to this differ-
ence: insuline resistance, arterial hypertension, and the
alterations  in  the  lipid  profile  with  the  resulting
dyslipide  mia and lipodystrophy. the increases in ldl
cholesterol lead to more ldl oxidation and uptake by
macro  phages, thereby contributing to plaque progres-
sion. 
- HIV-infected patients are a high-risk group
HIV-infected patients, like diabetics, belong to a car-
diovascular high-risk group. Risk factors such as hy-
pertension,  diabetes,  hyperlipidemia,  and  smoking
should be reduced. Moreover, investigations of vascu-
lar function, the measurement of inflammatory mark-
ers (e.g. cRP), and statin treatment with its lipid-low-
ering and anti-inflammatory effects could be used to
assess and manage cardiovascular risks.
the  clear-cut  effect  of  statins  on  cardiovascular
events  was  demonstrated  in  the  JuPItER  trial:  Al-
most 18000 healthy subjects without diabetes or car-
diovascular  disease  and  an  ldl  cholesterol  level  of
<130 mg/dl as well as an hs-cRP level of 2-5 mg/l re-
ceived rosuvastatin or Placebo. In these subjects with
low-level inflammation, rosuvastatin reduced the cu-
mulative rate of cardiovascular events by 44% [83]. 
It is currently unclear if cRP is more than just a
surrogate parameter, i.e. that it acts as a mediator of
inflammatory  processes.  Markers  such  as  hs-cRP,
measures of endothelial function and vascular imaging
techniques require further validation in HIV-infected
patients. 
IMMunE ActIVAtIon: gEnEtIc fActoRs
(J. bogner, M￼nchen)
When  compared  with  death  due  to  cardiovascular
events or malignant tumours, death due to infection
has the strongest association with genetics [84]. the
strong association between severity of disease and ge-
netic background of the individual also applies to HIV
infection. 
the most important areas for which genetic poly-
morphisms  have  been  identified  that  influence  HIV
pathogenesis:  cytokines  that  interfere  with  immune
regulation  and  activation,  the  control  of  viral  entry
into the host cell, and polymorphisms that influence
adaptive immunity. 
- Severity of  disease
tnf-alpha is known to be a cofactor for AIds de-
mentia, with some data pointing at an impact of ge-
netic polymorphisms on its manifestation: the tnf-al-
pha-308  A  allele  is  more  frequent  in  patients  with
AIds  dementia  than  in  controls  (0.28  versus  0.007;
oR  5.5;  95%  cI  1.8-17.0)  [85].  Patients  with  sepsis
and  IRIs  also  show  an  over-representation  of  the
tnf-alpha-308 A allele. 
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A naturally occurring inhibitor of Il-1-Il-1ra antago-
nizes Il-1 receptor binding competitively. two differ-
ent alleles (Il-1Rn*1 with 4 tandem repeats and Il-
1Rn*2 with 2 tandem repeats) have been described.
Homozygosity  is  rare  and  is  associated  with  an  in-
creased  pro-inflammatory  response.  Il-1ra  reduced
HIV replication in vitro. HIV plasma viremia is signifi-
cantly lower in Il-1Rn+2 homozygous women, and
this polymorphism is more frequent in caucasian than
in non-caucasian women [86]. Meanwhile, 13 different
polymorphisms have been described in a french co-
hort, with their different distribution being associated
with differences in the course of HIV infection [87].
Virologic treatment response was associated with the
presence of the Il-1alpha-Allels Il1A889*2 allele in
an Australian cohort; however, the Il-1a-genotype had
no impact on cd4+ t-cell count [88].
- T-cell regeneration
Il-7 plays a pivotal role in t-cell thymopoiesis, with an
inverse  correlation  between  Il-7  plasma  level  and
cd4+ t-cell count. the expansion of cd4+ and cd8+
t-cells  is  stimulated  by  Il-7  [89].  A  three  base-pair
deletion in the Il-7 gene increases Il-7 expression and
results in a different course of cd4+ t-cells [90].
- Immune reconstitution
IRIs as a special state of immune activation is also in-
fluenced by genetic factors. different genetic profiles
such as the major histocompatibility complex alleles
HlA-A2 and HlA-b44 were found to be associated
with cMV end-organ disease as IRIs manifestation,
and increased Il-6 levels as well as increased ccR5
expression  were  associated  with  an  increased  occur-
rence of IRIs [91].
the regeneration of immunity during antiretroviral
therapy is influenced by a variety of genetic polymor-
phisms.  the  multivariate  analysis  of  data  obtained
from 873 treatment-na￯ve patients yielded 137 single
nucleotide Polymorphisms (snPs) in 17 genes, all of
which had a measurable impact on the magnitude of
cd4+ t-cell increase [92].
IMMunE ActIVAtIon And tuMouR RIsk
(c. Hoffmann, Hamburg)
the risk of malignancy in AIds patients showed clear
trends in the time-period between 1996 to 2002: the
standardized  incidence  ratios  in  comparison  to  the
general  population  decreased  for  kaposi’s  sarcoma
and – albeit to a lesser extent – for non Hodgkin’s
lymphoma (nHl). In contrast, the incidence of cervi-
cal cancer and non AIds-defining malignancies (non-
AdM)  remained  essentially  unchanged,  with  the  ex-
ception  of  Hodgkin’s  lymphoma.  kaposi’s  sarcoma,
nHl, and non-AdM all represent a third of all malig-
nant tumours diagnosed in HIV-infected patients [93].
of  note,  the  increase  of  Hodgkin’s  disease  in  the
HAARt era was observed in several cohorts. In the
german AIds-related lymphoma (ARl) cohort more
patients were diagnosed with Hodgkin’s disease than
with nHl [94]. It is hypothesized that the increase in
Hodgkin’s disease is not a direct effect of HAARt,
but that the HAARt-associated increase in cd4+ t-
cell counts provides a suitable milieu with growth sig-
nals  for  proliferation  and  survival  of  the  neoplastic
Reed-sternberg cells, which represent only about 1%
of all cells in Hodgkin tissue [95]. 
In 2005 16% of all deaths in patients with HIV in-
fection  were  due  to  non-AdM,  more  than  the  ob-
served  11%  in  2000  [96].  tumour-related  mortality
(non-AdM and AdM) is currently higher than mortal-
ity due to AIds-related infectious complications, with
approximately one third of all fatalities in HIV-infect-
ed patients being due to malignancy. 
once antiretroviral therapy is started, the likelihood
of kaposi’s sarcoma and nHl is clearly reduced [97]. 
Mortality in the sMARt study [43] was mainly due
to non-AdM, with no difference between the study
arms.  AIds-defining  malignancies  (AdM),  however,
occurred significantly more frequently in the treatment
interruption  arm  [98].  the  risk  of  fatal  AdM  and
non-AdM in the d:A:d-studie was inversely correlat-
ed with cd4+ t-cell count [99]. 
A meta-analysis of cancer incidence in HIV-infect-
ed patients (7 studies with 444.172 patients) compared
with  patients  with  renal  transplants  (5  studies  with
31.977  patients)  showed  an  increased  occurrence  of
many tumours in both groups [100]. When compared
with HIV-infected patients, renal transplant recipients
showed  a  higher  incidence  of  colorectal  carcinoma,
melanoma, bladder carcinoma, lymph node cancer, re-
nal cancer, vulva- and vaginal carcinoma and oral can-
cer). the incidence of malignancy was higher only for
a few kinds of tumours: Hodgkin’s lymphoma, nHl,
and kaposi’s sarcoma.
- Direct impact of  immune activation on lymphoma
Apart  from  HIV  infection  itself,  other  mechanisms
such as oncogenic viruses, age, alcohol, and nicotine
might  contribute  to  increased  lymphoma  rates.  Im-
munodeficiency, however, is the major risk factor for
AdM  as  well  as  for  non-AdM.  there  is  some  evi-
dence for a role of immune activation in lymphomage-
nesis, but there is no direct proof of b-cell activation
as a cause of lymphoma. the clinical manifestation of
lymphoma is relatively homogeneous, with 60-80% of
diagnoses  made  in  late  stages,  70-80%  extranodal
manifestations,  more  than  90%  high-risk  subtypes
with high proliferation rates, low remission rates, high
probability of relapse, and an unfavourable diagnosis
without HAARt. 
the underlying pathogenetic mechanisms leading to
lymphoma, however, are probably heterogeneous. this
is  reflected  in  differences  in  cd4+ t-cell  counts  at
manifestation, e.g. around 300 cells/ﾵl for burkitt-like
lymphoma,  as  opposed  to  less  than  20  cells/ﾵl  for
primary central nervous system lymphoma (Pc-nHl).
Moreover, malignant transformation appears to occur
at different stages of cellular differentiation. the asso-
ciation with Epstein-barr Virus (EbV) is also differ-
ent: the closer the association, the more profound is
immune deficiency. 
b-cell stimulation appears to be a risk factor for
nHl.  this  view  is  supported  by  several  different 
observations. nHl cases had higher serum globuline
levels cases compared with controls before the onset
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in  the  MAcs  cohort  had  a  higher  expression  of
cd30, which is expressed by type 2 t-cells and stimu-
lates the release of b-cell-stimulating cytokines [102].
furthermore,  the  activation-induced  cytidine  deami-
nase  (AId)  is  increased  in  burkitt-like  lymphomas 
as  compared  with  other  lymphomas  [103].  this
APobEg-like enzyme is expressed in germinal cen-
ter b-cells and is essential for somatic hypermutation
in the process of affinity maturation of b-cells. AId
is induced by oncogenic viruses and b-cell stimula-
tion.  there  is  insufficient  data  for  other  activation
markers like Il-10, cd44, cd27, and cd23, which
were mostly investigated on frozen samples from the
MAcs cohort. 
cumulative viremia during HAARt appears to con-
tribute to the risk of burkitt-like lymphoma, probably
because it drives b-cell activation [104]. In castleman’s
disease the level of HHV-8 viremia correlates tightly
with Il-6, Il-10, and cRP. HHV-8 produces a viral
Il-6, which has a 25% amino acid homology with hu-
man Il-6 and binds to the human Il-6 receptor. the
overproduction  of  viral  Il-6  and  the  activation  of
subsequent events in the inflammation cascade leads
to a massive activation of the immune system [105]. 
suMMARy of tHE dIscussIon
the question to which extent immune activation due
to HIV infection is more than just a reflection of a
physiological process can  not be answered clearly to
date. the answer could actually be very individual, with
genetic and environmental factors modulating the ex-
tent of immune activation and its sequelae, as well as
preexisting factors such as cardiovascular risk factors.
However, comparisons of non-pathogenic sIV infec-
tions in non-human primates with HIV-1 in humans
have confirmed the clear association of immune acti-
vation with pathogenesis. Especially in the sIV lineage
that gave rise to HIV-1, the viral protein nef appears
to play a pivotal role in persistent immune activation.
the relevance of HIV-induced immune activation
as a major driving factor of pathogenesis is reflected
in several cohort analyses and clinical studies investi-
gating  interruptions  of  antiretroviral  therapy,  which
suggest that, in addition to classical HIV-related clini-
cal events such as opportunistic infections, resurgence
of virus replication also promotes non AIds-defining
conditions such as coronary heart disease, osteoporo-
sis, hepatic and renal events and certain types of non-
Hodgkin’s lymphoma.
Moreover, in addition to HIV itself, persistent or
repeated coinfections such as cMV or concurrent sex-
ually transmitted diseases might act as triggers for im-
mune  activation.  the  most  extreme  example  of  a
physiological  reaction  against  concurrent  infections
that turns into a potentially detrimental phenomenon
would be IRIs. 
the persistence of increased levels of immune acti-
vation in some individuals with virus suppression on
HAARt raises the question if HIV pathogenesis con-
tinues even in the absence of measurable levels of ac-
tive  virus  replication.  the  association  of  “residual”
immune activation with a persistently increased risk of
infections  and  tumours  during  HAARt  in  cohort
studies should be investigated, but currently remains
hypothetical. It is also unclear if it just represents a
consequence of prior extensive cd4+ t-cell loss, as
reflected by incomplete recovery of cd4+ t-cells in
the  gastrointestinal  tract  and  elevated  lPs  levels  or
persistent functional t-cell defects, or if it plays an in-
dependent  pathophysiological  role.  the  prolonged
persistence  of  viral  antigens  on  follicular  dendritic
cells  in  the  lymph  node  despite  successful  HAARt
known to exert immunomodulatory functions, induce
t-cell loss or drive immune activation could also help
to explain persistent immune activation. 
Any clinical events propagated by such effects will
be overlapped by the dramatic reduction of clinical pro  -
gression by HAARt. As a consequence, large and well-
controlled cohort studies and prospective clinical trials
are required in order to characterize their importance.
the natural course of sIV infection in pathogenic
and  apathogenic  monkey  models  suggests  that  im-
mune activation plays a pivotal role in the pathogene-
sis of HIV infection. In view of the uncertainty re-
garding the feasibility of life-long antiretroviral thera-
py with currently available drugs, novel treatment ap-
proaches should be ivestigated which are not merely
directed towards virus replication but towards its con-
sequences for the host organism. 
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